AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd reported total revenue from operations of ₹2,255.48 lakhs for FY25, down from ₹2,712.48 lakhs in FY24 — a decline of about 16.8%. Net profit fell to ₹57.89 lakhs from ₹76.86 lakhs, a drop of roughly 24.7%, with basic EPS at ₹1.14 versus ₹1.51. The revenue dip was largely due to a temporary halt in production at the FFS section from January 2025 to upgrade to revised Schedule M / WHO-GMP norms (certification received on 27 March 2025). Despite weaker top line, operating cash flow improved sharply to ₹263.67 lakhs from ₹82.02 lakhs. Total equity rose to ₹950.38 lakhs and overall borrowings declined. The auditor gave an unmodified opinion but flagged four emphasis-of-matter items: a Kotak Mahindra Bank loan of ₹175 lakhs (taken Nov 2021) where no charge was registered (now fully repaid), write-back of old statutory dues (~₹5.28 lakhs), the production shutdown, and ₹23.75 lakhs of trade receivables written off as irrecoverable.
The decline reflects a temporary production disruption rather than structural weakness, and the WHO-GMP certification positions the company for potential recovery. However, the emphasis-of-matter notes — especially the unregistered loan charge and recurring receivable write-offs — flag governance concerns shareholders should watch, even though no audit qualifications were raised.